Darrell White, Adetola Kassim, Birbal Bhaskar, Jing Yi, Karen Wamstad and Virginia E. Paton Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma Cancer 119
Version of Record online: 18 JUL 2012 | DOI: 10.1002/cncr.27745
The addition of bevacizumab to bortezomib in unselected patients with pretreated multiple myeloma does not result in significant improvements in efficacy outcomes. The combination is well tolerated, and the current results identify no new safety concerns for either agent.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field